Tarsus Pharmaceuticals, Inc. · NASDAQ:TARS
Tarsus Pharmaceuticals — Jefferies Virtual London Healthcare Conference 2020
21 slides from Tarsus Pharmaceuticals's conference presentation, Nov 17, 2020
Slide 1: Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Jefferies Virtual London Healthcare Conference November 17, 2020
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements that involve risks and uncertainties. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and finan
Slide 3: Tarsus Board and Executive Team
Tarsus Board and Executive Team Board of Directors Executive and Management Team Andrew Goldberg Bhaskar Chaudhuri Bobby Azamian Michael Ackermann Sesha Neervannan Aziz Mottiwala Leo Greenstein CEO Chairman COO CCO CFO Bill Link Jason Tester Michael Ackermann, Chairman Elizabeth Yeu Mark Holdbrook K
Slide 4: Corporate Highlights
Corporate Highlights Potential for first-ever Completed five clinical FDA-approved trials, including two Commenced therapeutic for Demodex Phase 2b randomized Phase 2b/3 blepharitis. Significant control trials. enrollment in market opportunity with no Consistently met safety September 2020 approved
Slide 5: Our Mission
Our Mission To discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye © Tarsus Pharmaceuticals: Confidential & Proprietary 5
Slide 6: Blepharitis is a Large and Underserved Market in Eye Care
Blepharitis is a Large and Underserved Market in Eye Care Epidemiology of Demodex Blepharitis Estimated In-Office Largely ~ 58% of all patients in the eye clinic have collarettes2 Epidemiology Underdiagnosed, but current impression of only 10-15% of blepharitis cases ~25M Education Needed ◦ ~45M uni
Slide 7: Blepharitis has Potential Similarities to Dry Eye Market Years Ago
Blepharitis has Potential Similarities to Dry Eye Market 15 Years Ago Potential Large Latent Demand for a New Therapy • Dry eye is a similar ocular surface disease to Blepharitis, that is likewise treated by ECPs* Dry Eye ICD Diagnoses/Year 7,000,000 • Large untapped patient population that was acti
Slide 8: Half of All Patients Entering Clinic have Collarettes
Half of All Patients Entering Clinic have Collarettes • Since Demodex is newly appreciated as a cause of blepharitis, Tarsus performed the first-ever Demodex blepharitis in-clinic prevalence study • Methods: every consecutive patient seen by the clinic is evaluated for 1. Presence of collarettes (th
Slide 9: Collarettes Are Pathognomonic Sign of Demodex Infestation
Collarettes Are Pathognomonic Sign of Demodex Infestation Collarettes Are Composed of Mite Waste Products and Eggs1 • Regurgitated undigested material combined with epithelial cells, keratin, and mite eggs • Contain digestive enzymes, which cause irritation % of Subjects with Demodex Easily and Rapi
Slide 10: TP-03 is a Novel Therapeutic Designed to Eradicate Demodex Mites
TP-03 is a Novel Therapeutic Designed to Eradicate Demodex Mites and Treat Demodex Blepharitis TP-03 is designed to paralyze the mite nervous system through parasite-specific GABA inhibition Lotilaner • Potent non-competitive antagonist of insect and arachnid GABA-Cl channels • Highly lipophilic mol
Slide 11: TP-03 is a Novel Drug Designed to Treat Demodex Blepharitis
TP-03 is a Novel Drug Designed to Treat Demodex Blepharitis by Eradicating Mites and Collarettes1 Product Form Multi-dose eye drop solution bottle, preserved Targeted Use Treatment of Demodex blepharitis MOA Paralysis and death of Demodex mites Diagnosis Collarettes identified in standard eye examin
Slide 12: Extensive Clinical Trial Program for TP-03
Extensive Clinical Trial Program for TP-03 Trial / Study Design Endpoints Results Achieved Status Ex-vivo mite 100% mites dead within 24 hours PoC: Mercury Ex-vivo mite testing on 80 mites death count (p < 0.001) Collarette Cure Mite Eradication Clinical Trials Rate** Rate 28-day BID dosing, single
Slide 13: Cure of Collarettes with BID Use of TP-03
Cure of Collarettes with BID Use of TP-03 Baseline Day 28 © Tarsus Pharmaceuticals: Confidential & Proprietary 13
Slide 14: Europa Phase 2b: Results Consistent with Jupiter Trial
Europa Phase 2b: Results Consistent with Jupiter Trial Primary and secondary efficacy endpoints same as Saturn-1 trial Collarette Cure (0-2 collarettes)* Mite Eradication (0 mites) (N=23,20) (N=18,18) (N=15,19) * The primary efficacy endpoint was the proportion of patients experiencing a cure based
Slide 15: Europa Phase 2b: Statistically Significant Composite Cure Rate
Europa Phase 2b: Statistically Significant Composite Cure Rate Lid erythema cure + collarette cure, FDA-requested additional secondary endpoint Composite Cure (Erythema Cure + Collarette Cure) Erythema + Collarette Cure (Analysis Eye) © Tarsus Pharmaceuticals: Confidential & Proprietary 15
Slide 16: TP-03 Clinical Data Show Recurrence Rate of Demodex Blepharitis Post-Treatment
TP-03 Phase 2 Clinical Data Show Recurrence Rate of Clinical-Grade Demodex Blepharitis Post-Treatment Post treatment data from Mars & Jupiter trials show recurrence of both collarettes & mite density >10 Collarettes on Lid Mite Density of 1.0 or More Post-treatment follow-up Post-treatment follow-up
Slide 17: Market Research Shows Positive Reaction from Providers and Patients
Market Research Shows Positive Reaction from Providers and Patients After exposure to information on collarettes, Demodex blepharitis and TP-03 Phase 2 data Clinician Prescribing Intention Patient Intention to Seek a Doctor 100% of ECPs indicated would prescribe 1L or 2L 92% of blepharitis patients
Slide 18: TP-03 has Significant Market Potential in Demodex Blepharitis
TP-03 has Significant Market Potential in Demodex Blepharitis Opportunity comparable to established ophthalmic therapeutics Large addressable patient population • High prevalence of an estimated 25 million patients and untapped educational opportunity similar to Dry Eye* • 2.1 million current ICD-10
Slide 19: Pipeline with Different Formulations of Novel API
Pipeline with Different Formulations of Novel API Anticipated clinical trial events in our programs in 2021 Anticipated Future Candidate Indication Formulation Preclinical Phase 1 Phase 2 Phase 3 Milestones * Worldwide Rights 2021: Top line data results for Phase 2b/3 Saturn-1 trial Demodex blephari
Slide 20: Tarsus Summary
Tarsus Summary • TP-03 is a novel therapeutic with potential to be the first FDA-approved therapeutic and the standard of care for the treatment of Demodex blepharitis • Clinical efficacy and safety endpoints consistently achieved across multiple Phase 2 studies • Phase 2b/3 Saturn-1 currently enrol
Slide 21: © Tarsus Pharmaceuticals: Confidential & Proprietary
© Tarsus Pharmaceuticals: Confidential & Proprietary 21
Tarsus Pharmaceuticals — Jefferies Virtual London Healthcare Conference 2020 on 6ix